Releases - Biotage

View:

2009

 

Found press releases

 

Biotage moves to 100% direct sales for SPE products in the UK

12/16/2009 3:05 AM EST
Biotage is expanding its direct sales coverage and will begin selling SPE products directly into non-pharma application areas within the UK starting January 18, 2010. Sales to non-pharmaceutical based markets and customers have previously been managed by a distributor.

Biotage ISOLUTE® and EVOLUTE® sample preparation products are available in a variety of media types and formats for bioanalytical, forensic,...

Interim report January-September 2009

10/27/2009 3:30 AM EST
Third quarter 2009
• Net sales decreased by 2 percent to 90.6 MSEK (92.3). At comparable exchange rates sales decreased by 13 percent.
• The operating result amounted to 2.0 MSEK (7.0).
• The result after tax amounted to 1.4 MSEK (6.6).
• Earnings per share amounted to 0.01 SEK (0.14).
• Net cash at September 30, 2009 amounted to 326.6 MSEK.
• As a part of Biotage’s buy-back program 158,779 own shares...

Biotage AB Nomination Committee

10/19/2009 5:40 AM EST
A Nomination Committee consisting of shareholder representatives and the Chairman of the Board of Directors has been formed for Biotage AB. The Nomination Committee shall, before the Annual General Meeting 2010, prepare proposals for the election of Chairman and other members of the Board of Directors, the election of Chairman of the Annual General Meeting, the determination of fees and matters pertaining...

Interim report for Biotage January - June 2009

8/14/2009 2:05 AM EST
• Net sales in the second quarter increased by 10 percent to 104.4 MSEK (95.1). In the period January – June 2009 net sales increased by 11 percent to 204.0 MSEK (184.0). At comparable exchange rates sales decreased by 10 percent, in the second quarter as well as during the first six months.
• The operating result amounted to 3.7 MSEK (2.7) in the second quarter and to -15,7 MSEK (3.9) in the period January - June....

Biotage AB launches share buy-back

6/22/2009 5:25 AM EST
The board of directors of Biotage AB (publ) has resolved to start a share buy-back program in accordance with the Annual General Meeting’s resolution to authorize the board to decide on the acquisition and sale of the company’s own shares.
At the Annual General Meeting held on 27 April 2009, the board was authorized to decide on the acquisition and sale of the company’s own shares up and until the forthcoming...

Resolutions at the Annual General Meeting in Biotage AB on April 27, 2009

4/28/2009 1:05 AM EST
At the Annual General Meeting held in Biotage AB (Reg. No. 556539-3138) on April 27, 2009, the following resolutions were passed, among others.

Appropriation of the company’s result
The General Meeting resolved a dividend of SEK 0.20 per share, which in aggregate is a dividend in the amount of SEK 17,697,264, and that accumulated profits of SEK 855,373,349 should be carried forward.

Record date for dividend...

Interim report January – March 2009

4/27/2009 9:14 AM EST
• Net sales increased by 12 percent to 99.6 MSEK (88.9). At comparable exchange rates sales decreased by 9 percent.
• Estimated restructuring costs for the closing of the production plant in the USA and consolidation of the operations in the UK have affected the result to the amount of 21.2 MSEK.
• The operating profit amounted to -19.4 MSEK (1.2) respectively to 1.8 MSEK before estimated restructuring costs.
•...

Biotage is subject to patent litigation in the US

4/22/2009 2:40 AM EST
Biotage AB has together with its subsidiaries Biotage GB Ltd and Biotage LLC been sued for patent infringement in the U.S. District court for the Southern District of California.
The lawsuit has been filed by Scientific Plastic Products, Inc. and concerns the US patents no 7,138,061, 7,381,327 and 7,410,571 each entitled ”Flash Chromatography Cartridge”. The law suit concerns Biotage’s sale of the product line...

Biotage AB (publ) releases its 2008 Annual Report

4/8/2009 2:30 AM EST
Biotage is today releasing its 2008 annual report.

The company generated net sales of 385,3 MSEK (397,6 MSEK).

The operating result amounted to 22,5 MSEK (16,7 MSEK) and total profit after tax for the year of 299,1 MSEK (99,4 MSEK).

Total profit per share of 3,38 SEK (1,12 SEK).

Financial Goals 2009 and onwards
Biotage business is under changes after the divestment of the Biosystems business and the...

NOTICE OF ANNUAL GENERAL MEETING IN BIOTAGE AB

3/27/2009 4:00 AM EST
The shareholders in Biotage AB are hereby summoned to the annual general meeting (the “Meeting”), to be held on Monday, April 27, 2009, at 4.00 p.m., at the head office of Biotage AB, Kungsgatan 76 in Uppsala, Sweden.

Notice etc.
Shareholders who wish to participate in the Meeting must
a) be recorded as a shareholder in the share register maintained by Euroclear Sweden AB (former VPC AB) on Tuesday, April 21,...

Biotage

Biotage accelerates the drug discovery and development process and increases the knowledge of the importance of the genetic make-up by providing complete solutions for medicinal chemistry research and applied genetic ana...

View more


  CONTACT